We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.47 | -0.44% | 105.50 | 107.16 | 105.91 | 106.43 | 4,096,958 | 23:43:21 |
From May 2021 to May 2024
By Will Feuer
Abbott Laboratories raised its full-year Covid-19 testing-related sales guidance, but lowered its expectations for annual earnings.
The Abbott Park, Ill.-based medical-products company said it now expects about $4.5 billion in Covid-19 testing-related sales for the year, with much of that expected to occur in the first half of the year. In January, the company said it expected Covid-19 testing sales of about $2.5 billion.
In 2021, the company recorded about $7.7 billion in Covid-19 testing-related sales.
Abbott lowered its full-year guidance for earnings to at least $3.35 a share from at least $3.43 a share previously. The company maintained adjusted earnings from continuing operations guidance of at least $4.70 a share.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
April 20, 2022 08:13 ET (12:13 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
